- Title: Subtitle
- Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival
- Creators
- Charlotte B Wagner - Huntsman Cancer InstituteDaniel A. Ermann - Huntsman Cancer InstituteKen Boucher - Huntsman Cancer InstituteAdrienne N. Nedved - 4Department of Pharmacy, Mayo Clinic, Rochester, MNIvana N. Micallef - Mayo Clinic in FloridaSanjal H Desai - University of MinnesotaHaris Hatic - University of AlabamaGaurav Goyal - University of Alabama at BirminghamErin Zacholski - Virginia Commonwealth UniversityAmanda Fegley - Virginia Commonwealth UniversityAudrey M. Sigmund - The Ohio State UniversityDavid A. Bond - The Ohio State UniversityCourtney Samuels - University of Colorado Cancer CenterManali K. Kamdar - University of Colorado Cancer CenterSheeba Ba AqeelPallawi Torka - Roswell Park Cancer InstituteKira MacDougall - 15University of Oklahoma Health, Oklahoma City, OKAzra Borogovac - University of Oklahoma Health Sciences CenterSridevi Rajeeve - Mount Sinai HospitalSuchitra Sundaram - Mount Saint Vincent UniversityKalub Fedak - The Barbara Ann Karmanos Cancer InstituteDipenkumar Modi - The Barbara Ann Karmanos Cancer InstituteElizabeth Travers - University of Kentucky HealthCareSabarish Ayyappan - University of IowaNitin Chilakamarri - University of California, IrvineElizabeth A Brem - University of California, IrvineDeborah M. Stephens - Huntsman Cancer InstituteBoyu Hu - Huntsman Cancer InstituteLindsey A. Fitzgerald - Huntsman Cancer InstituteHarsh Shah - University of Utah
- Resource Type
- Abstract
- Publication Details
- Blood, Vol.140(Supplement 1), pp.9390-9392
- DOI
- 10.1182/blood-2022-159001
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 11/15/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984361567402771
Abstract
Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival
Blood, Vol.140(Supplement 1), pp.9390-9392
11/15/2022
DOI: 10.1182/blood-2022-159001
Details
Metrics
11 Record Views